Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis

Pathophysiology

Volumn 17, Issue 4, 2010, Pages 295-306

  Weller, R O ^a   Galea, I ^a   Carare, R O ^a   Minagar, A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cerebral amyloid angiopathy; Cerebrospinal fluid; Dendritic cells; Imprinting; Interstitial fluid; Lymphatic drainage of the central nervous system; Lymphocyte trafficking; Multiple sclerosis; T cells; Tolerance

Indexed keywords

AMYLOID BETA PROTEIN;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ARTERY DISEASE; B LYMPHOCYTE; BASEMENT MEMBRANE; CELL MIGRATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CERVICAL LYMPH NODE; HUMAN; IMMUNOLOGICAL TOLERANCE; INTERSTITIAL FLUID; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ELIMINATION FAILURE ARTERIOPATHY; REVIEW; T LYMPHOCYTE;

EID: 77955511942     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2009.10.007     Document Type: Review

References (99)

1. Galea I., Bechmann I., Perry V.H. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18.
2. Love S., Wiley C.A. Viral infections. Greenfield's Neuropathology 2002, 1275-1389. Hodder Arnold, London. 8th ed.
3. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
4. Lassmann H. Models of multiple sclerosis: new insights into pathophysiology and repair. Curr. Opin. Neurol. 2008, 21:242-247.
5. Lassmann H., Brück W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
6. Pals S.T., de Gorter D.J., Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007, 110:3102-3111.
7. von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 2000, 343:1020-1034.
8. Yamada S., DePasquale M., Patlak C.S., Cserr H.F. Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am. J. Physiol. Heart Circ. Physiol. 1991, 261:30-34.
9. Harling Berg C., Knopf P.M., Merriam J., Cserr H.F. Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid. J. Neuroimmunol. 1989, 25:185-193.
10. Cserr H.F., Harling-Berg C.J., Knopf P.M. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992, 2:269-276.
11. Phillips M.J., Needham M., Weller R.O. Role of cervical lymph nodes in autoimmune encephalomyelitis in the Lewis rat. J. Pathol. 1997, 182:457-464.
12. Phillips M.J., Weller R.O., Kida S., Iannotti F. Focal brain damage enhances experimental allergic encephalomyelitis in brain and spinal cord. Neuropathol. Appl. Neurobiol. 1995, 21:189-200.
13. Sun D., Tani M., Newman T.A., Krivacic K., Phillips M., Chernosky A., Gill P., Wei T., Griswold K.J., Ransohoff R.M., Weller R.O. Role of chemokines, neuronal projections, and the blood-brain barrier in the enhancement of cerebral EAE following focal brain damage. J. Neuropathol. Exp. Neurol. 2000, 59:1031-1043.
14. Lake J, Weller R.O., Phillips M.J., Needham M. Lymphocyte targeting of the brain in adoptive transfer cryolesion-EAE. J. Pathol. 1999, 187:259-265.
15. van Zwam M., Huizinga R., Heijmans N., van Meurs M., Wierenga-Wolf A.F., Melief M.-J., Hintzen R.Q., 't Hart B.A., Amor S., Boven L.A., Laman J.D. Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing EAE. J. Pathol. 2009, 217:543-551.
16. Schwalbe G. Der Arachnoidalraum, ein Lymphraum und sein Zusammenhang mit dem Perichoroidalraum. Zentralb. Med. Wiss. 1869, 7:465-467.
17. Cserr H.F, Knopf P.M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 1992, 13:507-512.
18. Johnston M., Zakharov A., Papaiconomou C., Salmasi G., Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004, 1:2-15.
19. Weller R.O, Djuanda E., Yow H.Y., Carare R.O. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009, 117:1-14.
20. Foldi M., Csillik B., Zoltan O.T. Lymphatic drainage of the brain. Experimentia 1968, 24:1283-1287.
21. Bergsneider M. Evolving concepts of cerebrospinal fluid. Neurosurg. Clin. N. Am. 2001, 36:631-638.
22. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45:545-552.
23. Syková E., Nicholson C. Diffusion in brain extracellular space. Physiol. Rev. 2008, 88:1277-1340.
24. Carare R.O., Bernardes-Silva M., Newman T.A., Page A.M., Nicoll J.A.R., Perry V.H., Weller R.O. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries. Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 2008, 34:131-144.
25. Weller R.O., Massey A., Newman T.A., Hutchings M., Kuo Y.M., Roher A.E. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 1998, 153:725-733.
26. Preston S.D., Steart P.V., Wilkinson A., Nicoll J.A.R., Weller R.O. Capillary and arterial amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol. Appl. Neurobiol. 2003, 29:106-117.
27. Weller R.O., Subash M., Preston S.D., Mazanti I., Carare R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 2008, 18:253-266.
28. Szentistvanyi I., Patlak C.S., Ellis R.A., Cserr H.F. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 1984, 246:F835-844.
29. Schley D., Carare-Nnadi R., Please C.P., Perry V.H., Weller R.O. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J. Theor. Biol. 2006, 238:962-974.
30. Weller R.O., Boche D., Nicoll J.A. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol. 2009, (Epub ahead of print).
31. Revesz T., Ghiso J., Lashley T., Plant G., Rostagno A., Frangione B., Holton J.L. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol. 2003, 62:885-898.
32. Lowe J., Mirra S.S., Hyman B.T., Dickson D.W. Ageing and dementia. Greenfield's Neuropathology 2008, 1031-1152. Hodder Arnold, London. 8th ed.
33. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
34. Miners J.S., Baig S., Palmer J., Palmer L.E., Kehoe P.G., Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008, 18:240-252.
35. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106:1489-1499.
36. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007, 27:909-918.
37. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., Paul S.M., Zlokovic B.V., Piwnica-Worms D., Holtzman D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005, 115:3285-3290.
38. Vinters H.V., Wang Z.Z., Secor D.L. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain. Pathol. 1996, 6:179-195.
39. Shinkai Y., Yoshimura M., Ito Y., Odaka A., Suzuki N., Yanagisawa K., Ihara Y. Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels. Ann. Neurol. 1995, 38:421-428.
40. Wisniewski H.M., Wegiel J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol. (Berl.) 1994, 87:233-241.
41. Liddington R.C. Mapping out the basement membrane. Nat. Struct. Biol. 2001, 8:573-574.
42. Hardy J. Amyloid double trouble. Nat. Genet. 2006, 38:11-12.
43. Zhang-Nunes S.X., Maat-Schieman M.L., van Duinen S.G., Roos R.A., Frosch M.P., Greenberg S.M. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol. 2006, 16:30-39.
44. Davson H., Welch K., Segal M.B. Physiology and Pathophysiology of the Cerebrospinal Fluid 1987, Churchill Livingstone, Edinburgh.
45. Hutchings M., Weller R.O. Anatomical relationships of the pia mater to cerebral blood vessels in man. J. Neurosurg. 1986, 65:316-325.
46. Alcolado R., Weller R.O., Parrish E.P., Garrod D. The cranial arachnoid and pia mater in man: anatomical and ultrastructural observations. Neuropathol. Appl. Neurobiol. 1988, 14:1-17.
47. Nicholas D.S., Weller R.O. The fine anatomy of the human spinal meninges. A light and scanning electron microscopy study. J. Neurosurg. 1988, 69:276-282.
48. Johanson C.E., Duncan J.A., Klinge P.M., Brinker T., Stopa E.G., Silverberg G.D. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5:10.
49. Boulton M., Flessner M., Armstrong D., Hay J., Johnston M. Determination of volumetric cerebrospinal fluid absorption into extracranial lymphatics in sheep. Am. J. Physiol. 1998, 274:R88-96.
50. Kida S., Pantazis A., Weller R.O. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 1993, 19:480-488.
51. Weller R.O Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J. Neuropathol. Exp. Neurol. 1998, 57:885-894.
52. Galea I., Felton L.M., Waters S., van Rooijen N., Perry V.H., Newman T.A. Immune-to-brain signalling: the role of cerebral CD163-positive macrophages. Neurosci. Lett. 2008, 448:41-46.
53. Hatterer E., Touret M., Belin M.F., Honnorat J., Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS ONE 2008, 3:e3321.
54. Kivisäkk P., Mahad D.J., Callahan M.K., Sikora K., Trebst C., Tucky B., Wujek J., Ravid R., Staugaitis S.M., Lassmann H., Ransohoff R.M. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 2004, 55:627-638.
55. Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J. Neurol. Sci. 2008, 274:23-26.
56. Bechmann I., Galea I., Perry V.H. What is the blood-brain barrier (not)?. Trends Immunol. 2007, 28:5-11.
57. Bauer J., Bradl M., Hickley W.F., Forss-Petter S., Breitschopf H., Linington C., Wekerle H., Lassmann H. T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am. J. Pathol. 1998, 153:715-724.
58. Hochmeister S., Zeitelhofer M., Bauer J., Nicolussi E.M., Fischer M.T., Heinke B., Selzer E., Lassmann H., Bradl M. After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream. Am. J. Pathol. 2008, 173:1669-1681.
59. Fabriek B.O, Zwemmer J.N., Teunissen C.E., Dijkstra C.D., Polman C.H., Laman J.D., Castelijns J.A. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J. Neuroimmunol. 2005, 161:190-194.
60. de Vos A.F., van Meurs M., Brok H.P., Boven L.A., Hintzen R.Q., van der Valk P., Ravid R., Rensing S., Boon L., 't Hart B.A., Laman J.D. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. 2002, 169:5415-5423.
61. Carson M.J., Reilly C.R., Sutcliffe J.G., Lo D. Disproportionate recruitment of CD8+ T cells into the central nervous system by professional antigen-presenting cells. Am. J. Pathol. 1999, 154:481-494.
62. Ferrer I., Kaste M., Kalimo H. Vascular diseases. Greenfield's Neuropathology 2008, 121-240. Hodder Arnold, London. 8th ed.
63. Zhang E.T., Richards H.K., Kida S., Weller R.O. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol. 1992, 83:233-239.
64. Goldmann J., Kwidzinski E., Brandt C., Mahlo J., Richter D., Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J. Leukoc. Biol. 2006, 80:797-801.
65. Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998, 282:480-483.
66. Mullins D.W., Sheasley S.L., Ream R.M., Bullock T.N., Fu Y.X., Engelhard V.H. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 2003, 198:1023-1034.
67. Cavanagh L.L., Bonasio R., Mazo I.B., Halin C., Cheng G., van der Velden A.W., Cariappa A., Chase C., Russell P., Starnbach M.N., Koni P.A., Pillai S., Weninger W., von Andrian U.H. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat. Immunol. 2005, 6:1029-1037.
68. González Cámpora R, Otal Salaverri C., Vázquez Ramirez F., Salguero Villadiego M., Galera Davidson H. Metastatic glioblastoma multiforme in cervical lymph nodes. Report of a case with diagnosis by fine needle aspiration. Acta Cytol. 1993, 37:938-942.
69. Wenkel H., Streilein J.W., Young M.J. Systemic immune deviation in the brain that does not depend on the integrity of the blood-brain barrier. J. Immunol. 2000, 164:5125-5131.
70. Wolvers D.A., Coenen-de Roo C.J., Mebius R.E., van der Cammen M.J., Tirion F., Miltenburg A.M., Kraal G. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. J. Immunol. 1999, 162:1994-1998.
71. Kraal G., Samsom J.N., Mebius R.E. The importance of regional lymph nodes for mucosal tolerance. Immunol. Rev. 2006, 213:119-130.
72. Harling Berg C.J., Knopf P.M., Cserr H.F. Myelin basic protein infused into cerebrospinal fluid suppresses experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1991, 35:1-3.
73. Tsai C.Y., Chow N.H., Ho T.S., Lei H.Y. Intracerebral injection of myelin basic protein (MBP) induces inflammation in brain and causes paraplegia in MBP-sensitized B6 mice. Clin. Exp. Immunol. 1997, 109:127-133.
74. Mutlu L., Brandt C., Kwidzinski E., Sawitzki B., Gimsa U., Mahlo J., Aktas O., Nitsch R., van Zwam M., Laman J.D., Bechmann I. Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion. Exp. Brain Res. 2007, 178:542-553.
75. Goodin D.S., Ebers G.C., Johnson K.P., Rodriguez M., Sibley W.A., Wolinsky J.S. The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999, 52:1737-1745.
76. Galea I., Bernardes-Silva M., Forse P.A., van Rooijen N., Liblau R.S., Perry V.H. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007, 204:2023-2030.
77. Sigmundsdottir H., Butcher E.C. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat. Immunol. 2008, 9:981-987.
78. Compston A, Coles A. Multiple sclerosis. Lancet 2006, 359:1221-1231.
79. Lublin F.D. Clinical features and diagnosis of multiple sclerosis. Neurol. Clin. 2005, 23:1-15.
80. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
81. Confavreux C., Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging Clin. N. Am. 2008, 18:589-622.
82. Traboulsee A., Li D.K. Conventional MR imaging. Neuroimaging Clin. N. Am. 2008, 18:651-673.
83. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9:540-549.
84. Barkhof F., Scheltens P., Frequin S.T., Nauta J.J., Tas M.W., Valk J., Hommes O.R. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. Am. J. Roentgenol. 1992, 159:1041-1047.
85. Kermode A.G., Tofts P.S., Thompson A.J., MacManus D.G., Rudge P., Kendall B.E., Kingsley D.P., Moseley I.F., du Boulay E.P., McDonald W.I. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990, 40:229-235.
86. Cotton F., Weiner H.L., Jolesz F.A., Guttmann C.R. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003, 60:640-646.
87. Gasperini C., Pozzilli C., Bastianello S., Koudriavtseva T., Galgani S., Millefiorini E., Paolillo A., Horsfield M.A., Bozzao L., Fieschi C. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998, 50:403-406.
88. Pozzilli C., Bastianello S., Koudriavtseva T., Gasperini C., Bozzao A., Millefiorini E., Galgani S., Buttinelli C., Perciaccante G., Piazza G., Bozzao L., Fieschi C. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1996, 61:251-258.
89. Jaffe S.L., Minagar A. Demyelinating pseudotumor. Arch. Neurol. 2005, 62:1466-1467.
90. Lassmann H. Basic mechanisms of brain inflammation. J. Neural. Transm. Suppl. 1997, 50:183-190.
91. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
92. Sobel R.A., Moore G.R.W. Demyelinating diseases. Greenfield's Neuropathology 2008, 1513-1608. Hodder Arnold, London. 8th ed.
93. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
94. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
95. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
96. Magliozzi R., Columba-Cabezas S., Serafini B., Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:11-23.
97. Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., Gambini C., Mancardi G.L., Uccelli A., Pistoia V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:11064-11069.
98. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., Andreoni L., Trivedi P., Salvetti M., Faggioni A., Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204:2899-2912.
99. O'Neill E.J., Day M.J., Wraith D.C. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J. Neuroimmunol. 2006, 178:1-8.